Skip to content
MarketScale
‹ Back to IndustriesSciences

Falling Space Station Will Hit Earth

China’s 8.5-ton space station will come crashing down to Earth from Saturday onwards, the country’s space authorities said, although they can not confirm where it is likely to hit. The Tiangong-1, or “Heavenly Palace” lab, will hit the earth between March 31 and April 4 and “should” burn up in the atmosphere, Chinese space officials…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences ·
Share
Falling Space Station Will Hit Earth

Key takeaways

01

China’s 8.5-ton space station will come crashing down to Earth from Saturday onwards, the country’s space authorities said, although they can not confirm where it is likely to hit.

02

The Tiangong-1, or “Heavenly Palace” lab, will hit the earth between March 31 and April 4 and “should” burn up in the atmosphere, Chinese space officials…

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Request an invite

China’s 8.5-ton space station will come crashing down to Earth from Saturday onwards, the country’s space authorities said, although they can not confirm where it is likely to hit.

The Tiangong-1, or “Heavenly Palace” lab, will hit the earth between March 31 and April 4 and “should” burn up in the atmosphere, Chinese space officials said this week.

China’s first space lab was launched in 2011 and had “comprehensively fulfilled its historical mission” five years later.

It had ceased sending data and entered its “final phase of life” on March 16, according to a notice issued by the China Manned Space Engineering Office.

It is currently orbiting at an average height of about 216.2 kilometres, but experts are still unclear about the exact location of re-entry.

“It is impossible to name the exact reentry location at this stage”, an unnamed expert told the state-run Global Times newspaper.

Read the full article here

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

ENEOS ran an AI controller on a distillation column for 35 days and cut steam use 40%

ENEOS ran an AI controller on a distillation column for 35 days and cut steam use 40%

ENEOS Materials and Yokogawa ran an autonomous AI controller on a butadiene distillation column for 35 days and cut steam use 40%. It’s a real operations proof point. It also puts integration and governance gaps front and center.

  • 01A 35-day closed-loop run is a stronger autonomy proof point than a demo, it forces plants to prove handover, fallback, and KPIs over real feed and operating swings.
  • 02Steam reduction claims are compelling, but procurement and ops teams should pin vendors to baselines, operating envelopes, and how off-spec avoidance is measured.
  • 03Agentic AI is showing up as “work management” and “shift checklist” agents before it replaces control engineers, which shifts requirements toward clean, permissioned data access.

Sep 13, 2026

Novaspace sees 6,500+ Earth observation satellites by 2035, and value shifts to payload integration

Novaspace sees 6,500+ Earth observation satellites by 2035, and value shifts to payload integration

Novaspace forecasts more than 6,500 Earth observation satellites launching by 2035. It also projects $155.9 billion in manufacturing revenue, based on a SpaceNews-posted release dated Aug. 21, 2026. As defense-led demand shifts toward revisit rate and persistence, payload integration and fleet interoperability become the hard parts.

  • 01$155.9 billion is tied specifically to satellite manufacturing, not launch or ground, which should reshape how teams size supplier commitments and make-buy decisions.
  • 02Novaspace’s “skyscraper model” framing implies procurement power is shifting to payload integration, test capacity, and software-defined operations, even as the bus becomes more standardized.

Sep 13, 2026

Samsung Biologics signs $262M manufacturing deal through 2033, pushing longer CDMO bookings

Samsung Biologics signs $262M manufacturing deal through 2033, pushing longer CDMO bookings

Samsung Biologics disclosed a $262 million biologics manufacturing contract running through 2033. The work will be produced at Songdo, South Korea. The deal lifts Samsung Biologics’ cumulative contract value above $21.9 billion, per BioPharm International.

  • 01Duration is the headline: Samsung Biologics’ new $262 million contract with an unnamed European pharma company runs through Dec. 31, 2033, a long-dated commitment for the Songdo site (per BioPharm International).
  • 02CDMO selection is drifting from “price per batch” to “operating model”: Samsung Biologics executives have framed CDMOs as extensions of sponsor operations, which raises expectations for transparency, change control, and schedule flexibility (per BioPharm International).

Sep 13, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512